Michael Bigham - Aug 8, 2022 Form 4 Insider Report for Paratek Pharmaceuticals, Inc. (PRTK)

Role
Exec. Chairman of the Board, Director
Signature
/s/ William M. Haskell, Attorney-in-Fact for Michael Bigham
Stock symbol
PRTK
Transactions as of
Aug 8, 2022
Transactions value $
-$76,174
Form type
4
Date filed
8/10/2022, 09:00 PM
Previous filing
Mar 23, 2022
Next filing
Oct 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTK Common Stock Award $0 +143K +13.1% $0.00 1.24M Aug 8, 2022 Direct F1
transaction PRTK Common Stock Sale -$76.2K -28.6K -2.32% $2.66 1.21M Aug 9, 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Michael Bigham is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents performance-based restricted stock units ("PRSUs") granted on February 19, 2020 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 8, 2022.
F2 Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.58 to $2.78. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.